At ZRO, we focus on the acquisition, analysis, and interpretation of neuroimaging data in Phase I and Phase II studies in Alzheimer's disease and other neurodegenerative disorders. Additionally, we specialize in exploratory PET-based studies, which plays a pivotal role in the development of new PET tracers and provides essential preliminary data to guide critical decisions in clinical programs.

Our preclinical facilities further enable the evaluation of novel radiotracers using rodent and primate models, as well as in vivo drug labeling studies. Moreover, we offer our partners comprehensive, end-to-end solutions—ranging from study design and data acquisition to interpretation and even publication in high-impact journals—something truly unique in the industry.